Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 290 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Left-Sided Heart Failure Clear all
Terminated Not applicable Interventional

Reversible Pulmonary Artery Banding as Simplified Management of End-stage Dilated Left Ventriculopathy in Early Life

NCT02652676
View directory record Official record
Conditions
Acute on Chronic Systolic Congestive Heart Failure
Interventions
Reversible Pulmonary Artery Banding, GORE-TEX DualMesh EMERGE PLUS Biomaterial
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
Up to 4 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 22, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction

NCT00887588
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
LCZ696, Valsartan, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
11
States / cities
Little Rock, Arkansas • Chicago, Illinois • Detroit, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 22, 2026, 4:58 PM EDT
Terminated Not applicable Interventional

Syncardia 50cc TAH-t as a Bridge to Transplant

NCT02459054
View directory record Official record
Conditions
Heart Failure, Right-Sided, Cardiac Failure, Heart Failure, Left-Sided
Interventions
SynCardia 50cc temporary Total Artificial Heart (TAH-t)
Device
Lead sponsor
SynCardia Systems. LLC
Industry
Eligibility
10 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
26
States / cities
Tucson, Arizona • Los Angeles, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 22, 2026, 4:58 PM EDT
Completed Phase 1 Interventional

Safety Study of Chimeric Natriuretic Peptide(CD-NP) in Stable LVAD Patients

NCT01750905
View directory record Official record
Conditions
Left Ventricular Insufficiency
Interventions
CD-NP, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 22, 2026, 4:58 PM EDT
Completed Not applicable Interventional

Optimal Coronary Sinus Lead Implantation Using Intracardiac Impedography and Magnetic Resonance Imaging

NCT01129635
View directory record Official record
Conditions
Heart Failure, Systolic, Left Bundle Branch Block
Interventions
Cardiac Resynchronization Therapy (CRT) implantation
Procedure
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Oct 22, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Role of Endothelin in Pulmonary Hypertension

NCT00759408
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
BQ-123
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 22, 2026, 4:58 PM EDT
Recruiting Phase 2 Interventional

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

NCT06979362
View directory record Official record
Conditions
Heart Failure
Interventions
CDR132L, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
40 Years to 84 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
29
States / cities
Birmingham, Alabama • Tucson, Arizona • Covina, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 4:58 PM EDT
Not listed Phase 1 Interventional

VIVID - Valvular and Ventricular Improvement Via iCoapsys Delivery - Feasibility Study

NCT00512005
View directory record Official record
Conditions
Mitral Valve Regurgitation, Left Ventricular Dysfunction, Heart Failure, Mitral Insufficiency, Mitral Incompetence, Ischemic Heart Disease
Interventions
Percutaneous mitral valve repair
Device
Lead sponsor
Myocor
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
4
States / cities
Atlanta, Georgia • Evanston, Illinois • Shawnee Mission, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2009 · Synced Oct 22, 2026, 4:58 PM EDT
Completed No phase listed Observational

ELEVATE (Evaluation of Left Ventricular Autothreshold) 3.0

NCT01539629
View directory record Official record
Conditions
Heart Failure
Interventions
Cardiac pacing
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
4
States / cities
Davenport, Iowa • Yardley, Pennsylvania • Richmond, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Oct 22, 2026, 4:58 PM EDT
Completed No phase listed Observational

Validation of the Gated Blood Pool SPECT: ERNA vs 3D Echo

NCT00576186
View directory record Official record
Conditions
Congestive Heart Failure, Ventricular Function, Left
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Oct 22, 2026, 4:58 PM EDT
Terminated No phase listed Observational

The Epidemiology of Bleeding and Clotting in Patients Undergoing Heart Transplantation, Coronary Artery Bypass Graft Surgery,or Implantation of Left Ventricular Assist Devices

NCT01481012
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Birmingham, Alabama • San Diego, California • Oak Lawn, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2011 · Synced Oct 22, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure

NCT01786512
View directory record Official record
Conditions
Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction, Chronic Heart Failure, History of Chronic Heart Failure, Left Ventricular Ejection Fraction, Pharmacokinetics, Echocardiogram
Interventions
Omecamtiv Mecarbil Matrix F1 Formulation, Omecamtiv Mecarbil Matrix F2 Formulation, Placebo, Omecamtiv Mecarbil Swellable Core Technology F2
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
38
States / cities
Mobile, Alabama • Costa Mesa, California • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 22, 2026, 4:58 PM EDT
Terminated Phase 2 Interventional Results available

The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure

NCT01887353
View directory record Official record
Conditions
Atrial Fibrillation, Heart Failure
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jul 20, 2015 · Synced Oct 22, 2026, 4:58 PM EDT
Terminated Not applicable Interventional

Optimizing CRT With ECGI

NCT03492788
View directory record Official record
Conditions
Heart Failure, Systolic, Left Bundle-Branch Block
Interventions
ECGI-optimized VV-offset, Zero VV-offset
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 22, 2026, 4:58 PM EDT
Recruiting Not applicable Interventional

Left vs Left Randomized Clinical Trial

NCT05650658
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction, AV Block, LBBB, RBBB, Intraventricular Conduction Delay, Pacing-Induced Cardiomyopathy
Interventions
His/LBBP, BiVP
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
2,136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
57
States / cities
Gilbert, Arizona • Tucson, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 22, 2026, 4:58 PM EDT
Terminated Not applicable Interventional Results available

Dual Site Left Ventricular (LV) Pacing

NCT00944125
View directory record Official record
Conditions
Congestive Heart Failure, LV Dysfunction
Interventions
Dual Site LV Pacing, BiV Pacing
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Lake Geneva, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 22, 2026, 4:58 PM EDT
Recruiting Phase 1 Interventional

Study Assessing Left Ventricular Administration of a Genetic Medicine Directing Organ Regeneration in Heart Failure

NCT06831825
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
YAP101 (AAV9-Sav-shRNA)
Combination Product
Lead sponsor
Medley Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 22, 2026, 4:58 PM EDT
Terminated Phase 3 Interventional

INcrease Of VAgal TonE in CHF

NCT01303718
View directory record Official record
Conditions
Left Ventricular Dysfunction, Heart Failure
Interventions
CardioFit® System, Standard of Care
Device · Other
Lead sponsor
BioControl Medical
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
57
States / cities
Birmingham, Alabama • Mesa, Arizona • Glendale, California + 47 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 22, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

Attain Stability™ Quad Clinical Study

NCT03099655
View directory record Official record
Conditions
Heart Failure
Interventions
Attain Stability Quad Left Ventricular Pacing Lead
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
35
States / cities
Phoenix, Arizona • East Palo Alto, California • Torrance, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 22, 2026, 4:58 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)

NCT01300013
View directory record Official record
Conditions
Heart Failure
Interventions
Placebo, Omecamtiv mecarbil
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
45
States / cities
Mobile, Alabama • Inglewood, California • La Jolla, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 22, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

AdaptResponse Clinical Trial

NCT02205359
View directory record Official record
Conditions
Heart Failure With Left Bundle Branch Block
Interventions
aCRT ON, aCRT OFF
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
3,797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
90
States / cities
Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 22, 2026, 4:58 PM EDT
Withdrawn Phase 4 Interventional

CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression

NCT01275352
View directory record Official record
Conditions
Hypertension
Interventions
Eplerenone, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 22, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

HW006 LATERAL Thoracotomy

NCT02268942
View directory record Official record
Conditions
Left Sided Heart Failure
Interventions
HeartWare HVAD, Thoracotomy
Device · Procedure
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
19 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
25
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 22, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

NCT01807221
View directory record Official record
Conditions
Heart Failure
Interventions
Finerenone (BAY94-8862), Placebo, Inspra (eplerenone)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 22, 2026, 4:58 PM EDT